Inhibikase Therapeutics Stock Investor Sentiment

IKT Stock  USD 2.30  0.04  1.71%   
Slightly above 61% of Inhibikase Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Inhibikase Therapeutics suggests that many traders are alarmed. Inhibikase Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Inhibikase Therapeutics' earnings reports, geopolitical events, and overall market trends.
  

Inhibikase Therapeutics Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Inhibikase Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
54.7%
50.7%
50.7%
53.9%
51.4%
55.7%
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over three months ago at benzinga.com         
This Cytokinetics Analyst Begins Coverage On A Bullish Note Here Are Top 5 Initiations For Friday
benzinga news
over three months ago at gurufocus.com         
Director Arvind Kush Acquires 145,000 Shares of Inhibikase Therapeutics Inc
Gurufocus Stories at Macroaxis
over three months ago at investing.com         
Wednesdays Insider Activity Top Buys and Sells in US Stocks
Investing News at Macroaxis
over three months ago at investing.com         
Inhibikase therapeutics director Amit Munshi buys 500k in shares
Investing News at Macroaxis
over three months ago at investing.com         
Inhibikase therapeutics director Kush Arvind buys 198,650 in stock
Investing News at Macroaxis
over three months ago at investing.com         
Inhibikase Therapeutics director Bellini acquires 2m in stock
Investing News at Macroaxis
over three months ago at gurufocus.com         
Acquisition by Munshi Amit of 365000 shares of Inhibikase Therapeutics at 1.37 subject to Rule 16b-3
Gurufocus Stories at Macroaxis
over three months ago at news.google.com         
Perceptive Advisors LLC Acquires New Stake in Inhibikase Therapeutics Inc - Yahoo Finance
Google News at Macroaxis
over three months ago at finance.yahoo.com         
Inhibikase Therapeutics Announces Closing of up to 275 Million Financing and Advancement of IkT-001P...
Yahoo News
over three months ago at globenewswire.com         
Insider Trading
Macroaxis News: globenewswire.com
over three months ago at globenewswire.com         
Inhibikase Therapeutics Announces Closing of up to 275 Million Financing and Advancement of IkT-001P...
Macroaxis News: globenewswire.com
over three months ago at prnewswire.com         
Spolonos Huawei predstavila na GITEX GLOBAL 2024 vznamn lnok s nzvom Digitlna dividenda - vyspelos I...
prnewswire News
over three months ago at prnewswire.com         
Li Peng, hlavn viceprezident spolonosti a prezident predaja a sluieb IKT Huawei, predniesol na Huawe...
prnewswire News
over three months ago at thelincolnianonline.com         
HC Wainwright Lowers Inhibikase Therapeutics Price Target to 5.00
news
over three months ago at seekingalpha.com         
Inhibikase Therapeutics stock rises after pricing 110M private offering
seekingalpha News
Far too much social signal, news, headlines, and media speculation about Inhibikase Therapeutics that are available to investors today. That information is available publicly through Inhibikase media outlets and privately through word of mouth or via Inhibikase internal channels. However, regardless of the origin, that massive amount of Inhibikase data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Inhibikase Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Inhibikase Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Inhibikase Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Inhibikase Therapeutics alpha.

Inhibikase Therapeutics Performance against Dow Jones

 Price Growth (%)  
JavaScript chart by amCharts 3.21.15123456789101112Dec2025Feb 020406080100
JavaScript chart by amCharts 3.21.15Inhibikase Therapeutics Inhibikase Therapeutics Dividend Benchmark Dow Jones Industrial
       Timeline  
1
Disposition of 21853 shares by Milton Werner of Inhibikase Therapeutics at 2.02 subject to Rule 16b-3
12/09/2024
2
Inhibikase stock soars to 52-week high, hits 3.88 - Investing.com
12/16/2024
3
Acquisition by Berman Dennis N of 172191 shares of Inhibikase Therapeutics at 1.45 subject to Rule 16b-3
01/03/2025
4
Inhibikase Therapeutics expands authorized shares
01/06/2025
5
Disposition of 43707 shares by Ofarrell Elizabeth G. of Inhibikase Therapeutics at 5.57 subject to Rule 16b-3
01/17/2025
6
Bullish Inhibikase Therapeutics Insiders Loaded Up On US2.70m Of Stock
01/21/2025
7
Disposition of 5834 shares by Lees-rolfe Garth of Inhibikase Therapeutics at 3.79 subject to Rule 16b-3
01/22/2025
8
Insiders Enjoy US1.1m Return After Buying Inhibikase Therapeutics Stock - Simply Wall St
01/31/2025
9
Acquisition by Berman Dennis N of 620 shares of Inhibikase Therapeutics at 2.35 subject to Rule 16b-3
02/14/2025
10
Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Companys Growth
02/18/2025
11
Insider Trading
02/21/2025
12
Inhibikase Announces Expansion of Senior Leadership Team
02/24/2025

Additional Tools for Inhibikase Stock Analysis

When running Inhibikase Therapeutics' price analysis, check to measure Inhibikase Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inhibikase Therapeutics is operating at the current time. Most of Inhibikase Therapeutics' value examination focuses on studying past and present price action to predict the probability of Inhibikase Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inhibikase Therapeutics' price. Additionally, you may evaluate how the addition of Inhibikase Therapeutics to your portfolios can decrease your overall portfolio volatility.
News Freq…Investor S…